ABSORB III: after 3 Years, the Bioresorbable Scaffold is Still a Disappointment

Courtesy of the SBHCI.

The 3-year outcomes of the ABSORB III trial, which randomized 2008 patients 2:1 to an everolimus eluting bioresorbable scaffold (1322 patients) vs. a metallic stent with permanent everolimus eluting polymer (686 patients), was published with low profile and great disappointment.

ABSORB III: a 3 años continua la desilusión de la plataforma bioabsorbible

Primary end-point, a composite of target vessel failure, occurred in 13.4% of patients receiving the bioresorbable scaffold vs. 10.4% of patients receiving the Xience stent (p=0.06) at three-year follow up.


Read also: Absorb IV: Bioresorbable Scaffolds with an Optimized Implantation Technique”.


There was a significant increase in myocardial infarction rate associated to the target vessel lesion (8.6% vs. 5.9%; p=0.03), and an increase in definite/ thrombosis (2.3% vs. 0.7%; p=0.01) in the Absorb group.

 

Conclusion

At three-year follow up, the events rate was higher with the Absorb bioresorbable scaffold due to an increase in infarction rate associated to target vessel failure and definite/probable thrombosis.

 

Courtesy of the SBHCI.

 

Original title 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease.

Presenter: Stephen G. Ellis.

 

ABSORB-III


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

FLAVOUR Trial Substudy: FFR or IVUS in the Assessment of Diabetic Patients

Patients with diabetes often present with more complex coronary artery disease compared to non-diabetic patients, with a higher prevalence of diffuse or multivessel disease....

Mechanical Circulatory Support in Complex Anatomies and Severe Deterioration of Left Ventricular Function

Severe coronary artery disease (CAD) frequently causes left ventricular function deterioration, and is often treated with myocardial revascularization surgery (CABG), especially when ejection fraction...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...